The author explains why he avoids investing in Teva Pharmaceutical despite recognizing its opportunities. While Teva's traditional generic drug business is lucrative, increased competition has eroded profits. The company's pivot toward complex generics and original drug development introduces higher risk in a highly competitive sector. The author cites concerns about Teva's ability to pivot if its drug pipeline underperforms, contrasting it with larger competitors like Pfizer that have greater resources to adapt.

Teva Pharmaceuticals announced that the FDA has accepted its New Drug Application for TEV-749, an olanzapine extended-release injectable suspension for schizophrenia treatment. The once-monthly subcutaneous injection, based on Phase 3 SOLARIS trial results, aims to improve treatment adherence without requiring post-injection monitoring. The stock traded down 1.37% in premarket trading despite the positive regulatory milestone.

The FDA has accepted Teva Pharmaceuticals and Medincell's New Drug Application for TEV-'749, an investigational once-monthly subcutaneous olanzapine formulation for treating schizophrenia in adults. The Phase 3 SOLARIS trial demonstrated efficacy and safety consistent with current olanzapine formulations while eliminating the need for post-injection monitoring required by existing long-acting formulations, potentially addressing a significant treatment gap in schizophrenia care.

Teva Pharmaceutical and Sanofi announced positive results from the RELIEVE UCCD study of duvakitug, an investigational treatment for inflammatory bowel disease. The study demonstrated durable clinical efficacy over 44 weeks, with 58% of ulcerative colitis patients and 55% of Crohn's disease patients achieving primary endpoints at the 900 mg dose. TEVA shares rose 2.85% in premarket trading on the news.

Teva and Sanofi announced positive phase 2b long-term extension results for duvakitug, an investigational monoclonal antibody targeting TL1A for treating ulcerative colitis and Crohn's disease. The study showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients who initially responded to induction therapy, with remission rates of 47-58% in UC and 41-55% in CD depending on dosage. The drug was well tolerated with safety consistent with prior studies, supporting ongoing phase 3 development programs.

Sanofi and Teva announced positive phase 2b long-term extension results for duvakitug, an investigational monoclonal antibody targeting TL1A for treating ulcerative colitis and Crohn's disease. The RELIEVE UCCD LTE study showed durable clinical and endoscopic efficacy maintained over 44 weeks in patients who initially responded to induction therapy, with remission rates of 47-58% in UC and 41-55% in CD depending on dosage. The drug was well tolerated with safety consistent with prior studies, supporting ongoing phase 3 development programs.

Sanofi and Teva announced positive Phase IIb results for duvakitug, an experimental monoclonal antibody targeting TL1A, in treating ulcerative colitis and Crohn's disease. The RELIEVE UCCD LTE maintenance study showed sustained clinical and endoscopic efficacy over 44 weeks in patients who responded to initial induction therapy, with remission rates of 47-58% in UC and endoscopic response rates of 41-55% in CD. The drug was well-tolerated with a safety profile consistent with earlier studies. Both companies are advancing duvakitug into Phase III trials.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

Harel Insurance Investments & Financial Services Ltd. sold 4.177 million shares of the Invesco KBW Bank ETF (KBWB) worth approximately $330 million, reducing its position to virtually zero. The sale reflects concerns about lower interest rates pressuring bank profitability, with the proceeds being reallocated to healthcare and technology holdings.

Novo Nordisk faces a class action lawsuit alleging it unlawfully extended its monopoly over diabetes drug Victoza through an anticompetitive scheme designed to delay generic competition and shift patients to its newer GLP-1 drug Ozempic. The lawsuit claims Novo implemented a reverse payment agreement with Teva Pharmaceutical to delay generic Victoza launch until June 2024, preserving billions in profits and forcing purchasers to overpay for Victoza, its generics, and Ozempic.

Teva Pharmaceutical reported Q4 2025 revenue of $4.71 billion, beating expectations of $4.37 billion, with 11% YoY growth. The company's flagship drugs—Austedo, Ajovy, and Uzedy—collectively reached $1 billion in quarterly revenues for the first time. For 2026, Teva expects sales of $16.4-$16.80 billion and adjusted EPS of $2.57-$2.77, with multiple late-stage pipeline readouts anticipated.